.jpg?format=webp&width=780)
The study conducted a model‐based economic analysis of sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) versus dipeptidyl peptidase‐4 inhibitors (DPP4is) in patients with type 2 diabetes (T2D), with and without established cardiovascular diseases (CVDs), using 10‐year real‐world data. Use of SGLT2 is versus DPP4is was highly cost‐effective for patients with T2D regardless of their CVD history in real‐world clinical practice. The study results extend current evidence by showing SGLT2is as an economically rational alternative over DPP4is for T2D treatment in routine care. Future research is warranted to explore the heterogeneous economic benefits of SGLT2is given diverse patient characteristics in clinical settings.
Like
Save
Share